RxDoctor Payments Data

Sarah Buckingham, MD

Neurology · Stamford, CTNPI 1447549639

Payments from drug & device makers

$11,449in general payments, 2019–2025

Across 32 payments — averaging $357.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kyowa Kirin, Inc.$10K
  • SK Life Science, Inc.$383
  • Medtronic$280
  • AbbVie$162
  • Biohaven Pharmaceuticals, Inc.$118
  • Amgen$99
  • plus $221 from 3 others

What the payments were for

  • Speaking & faculty fees$9,97587%
  • Travel & lodging$1331%
  • Food & beverage$1,34112%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,449 in reported general payments places this provider in the 65th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$168,602
Medicare patients
530
Services billed
5,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate55$311,800
RytaryCarbidopa/Levodopa228$274,411
IngrezzaValbenazine Tosylate14$152,588
BotoxOnabotulinumtoxina80$141,845
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5015$97,602
GocovriAmantadine Hcl17$91,484
AustedoDeutetrabenazine13$62,434
NeuproRotigotine12$18,375
Carbidopa-LevodopaCarbidopa/Levodopa673$16,124
Aimovig AutoinjectorErenumab-Aooe12$12,892
Carbidopa-Levodopa ErCarbidopa/Levodopa170$9,004
Rasagiline Mesylate64$7,129
Rivastigmine26$5,218
Dimethyl Fumarate23$4,965
Bupropion XlBupropion Hcl19$3,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox$162$141,84580 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 280 neurology providers in Connecticut.

Other neurology in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →